Why we do what we do

dc.contributor.authorGalmarini, Carlos Maria
dc.date.accessioned2020-12-17T14:09:26Z
dc.date.available2020-12-17T14:09:26Z
dc.date.issued2020-10-28
dc.description.abstractThe goal of all medical activity is to preserve health in fit people, and to restore the sick into a state of complete physical, mental and social wellbeing. In an effort to determine whether we are achieving this last goal in oncology, herein we review the biological and clinical framework that has led to the foundations of the current anticancer treatment paradigm. Currently, cancer therapy is still based on the ancient axiom that states that the complete eradication of the tumor burden is the only way to achieve a cure. This strategy has led to a substantial improvement in survival rates as cancer mortality rates have dropped in an unprecedented way. Despite this progress, more than 9 million people still die from cancer every year, indicating that the current treatment strategy is not leading to a cancer cure, but to a cancer remission, that is “the temporary absence of manifestations of a particular disease”; after months or years of remission, in most patients, cancer will inevitably recur. Our critical analysis indicates that it is time to discuss about the new key challenges and future directions in clinical oncology. We need to generate novel treatment strategies more suited to the current clinical reality.en
dc.identifier.citationGalmarini, C. M. (2020). Why we do what we do. A brief analysis of cancer therapies. EXCLI Journal, 19, 1401-1413. https://doi.org/10.17179/excli2020-2972en
dc.identifier.issn1611-2156
dc.identifier.urihttp://hdl.handle.net/2003/39919
dc.identifier.urihttp://dx.doi.org/10.17877/DE290R-21809
dc.language.isoen
dc.publisherIfADo - Leibniz Research Centre for Working Environment and Human Factors, Dortmunden
dc.relation.ispartofseriesEXCLI Journal;Vol. 19 2020
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectNeoplasmen
dc.subjectMolecular targeted therapiesen
dc.subjectImmunotherapyen
dc.subjectArtificial intelligenceen
dc.subjectAntiangiogenic agentsen
dc.subject.ddc610
dc.titleWhy we do what we doen
dc.title.alternativea brief analysis of cancer therapiesen
dc.typeText
dc.type.publicationtypearticle
dcterms.accessRightsopen access
eldorado.dnb.deposittruede
eldorado.dnb.zdberstkatid2132560-1
eldorado.dnb.zdberstkatidtrue
eldorado.identifier.urlhttps://www.excli.de/index.php/excli/article/view/2972

Dateien

Originalbündel

Gerade angezeigt 1 - 1 von 1
Lade...
Vorschaubild
Name:
excli2020-2972.pdf
Größe:
1.3 MB
Format:
Adobe Portable Document Format
Beschreibung:
DNB

Lizenzbündel

Gerade angezeigt 1 - 1 von 1
Lade...
Vorschaubild
Name:
license.txt
Größe:
4.85 KB
Format:
Item-specific license agreed upon to submission
Beschreibung: